Prevalence of medication-related osteonecrosis of the jaw (MRONJ) in breast cancer patients receiving low-dose bone modifying agents for cancer treatment-induced bone loss (CTIBL): need for further data
本文未提供摘要，请点击“查看全文”查看完整内容。